טוען...
Comments on Immunogenicity Associated with Botulinum Toxin Treatment. Toxins 2019, 11, 491
In contrast to the prevailing arguments presented in the current review, the incidence of neutralising antibody (NAb) formation is not a significant issue for any of the present type A therapeutic botulinum neurotoxin (BoNT) products. Furthermore, clinical non-responsiveness is poorly correlated wit...
שמור ב:
| הוצא לאור ב: | Toxins (Basel) |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
MDPI
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7076756/ https://ncbi.nlm.nih.gov/pubmed/31979238 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/toxins12020071 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|